NOVAVAX INC (NVAX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVAX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | Independent Director; Founder and former Chief Executive Officer | 66 | ["Interim Chief Executive Officer at Biotechnology Innovation Organization (2022 to 2024)","Founder and former Chief Executive Officer at GlycoMimetics, Inc. (2003 to 2021)","Executive in Residence at New Enterprise Associates (2001 to 2003)","Senior Vice President at Novartis Corporation (1999 to 2001)","Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis (1996 to 1998)","Vice President for Product Planning at Novartis (1993 to 1996)","Manager of Laboratory Operations at Novartis (1989 to 1993)","M.B.A. from Harvard Business School","Bachelor of Arts from Dartmouth College","Industry Experience","Executive Leadership","Scientific, Research or Development Experience","Accounting, Financial or Investment Experience","Public Company Board"] | ["Compensation","Nominating & Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
AGE 66 INDEPENDENT DIRECTOR SINCE 2018 COMMITTEES Compensation Nominating & Corporate Governance RACHEL K. KING CAREER HIGHLIGHTS The Biotechnology Innovation Organization Interim Chief Executive Officer (2022 to 2024) GlycoMimetics, Inc. Founder and former Chief Executive Officer (2003 to 2021) New Enterprise Associates Executive in Residence (2001 to 2003) Novartis Corporation Senior Vice President (1999 to 2001) Genetic Therapy, Inc. Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis (1996 to 1998) Vice President for Product Planning (1993 to 1996) including early-stage development, initial public offering and acquisition by Novartis Manager of Laboratory Operations (1989 to 1993) OTHER CURRENT PUBLIC COMPANY BOARDS Fulcrum Therapeutics (Nasdaq: FULC) OTHER CURRENT DIRECTORSHIPS Biotechnology Innovation Organization University of Maryland BioPark Maryland Life Sciences Advisory EDUCATION M.B.A., Harvard Business School Bachelor of Arts, Dartmouth College KEY SKILLS AND QUALIFICATIONS Ms. King is well-suited to serve on our Board due to her successful growth and development of businesses and products, her experience as a chief executive officer of a public company, and her significant experience in governance, legal, finance, and risk management.